^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CD5 (CD5 Molecule)

    i
    Other names: CD5, CD5 Molecule, T-Cell Surface Glycoprotein CD5, Lymphocyte Antigen T1/Leu-1, CD5 Antigen (P56-62), LEU1, Epididymis Secretory Sperm Binding Protein, CD5 Antigen
    1d
    Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, Alliance Foundation Trials, LLC. | Trial completion date: Mar 2026 --> Aug 2026 | Trial primary completion date: Mar 2026 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule)
    |
    Chr t(11;14)
    |
    Ibrance (palbociclib) • Imbruvica (ibrutinib)
    2d
    Distinction of thymic carcinoma and type B3 thymoma using ancillary biomarkers. (PubMed, Pathologica)
    CD5 and CD117 are the best markers for TC. While the addition of other markers (i.e., BAP1 loss, MTAP loss and CDKN2A deletion) might be useful in cases negative for CD5 and CD117, rare cases of type B3 thymoma might harbor these alterations.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase) • BAP1 (BRCA1 Associated Protein 1) • CD5 (CD5 Molecule)
    |
    CDKN2A deletion • KIT expression
    3d
    Identification of Trogocytosis as an Essential Limitation Factor in hPSC-derived CAR Macrophages. (PubMed, Int J Biol Sci)
    In contrast, the retrieved iCAR-Ms from tumor cell co-culture retained tumoricidal activity on new tumor cell expressing CD5. Thus, we identify trogocytosis as an important limiting factor on iCAR-Ms therapy, providing a rationale for developing enhanced CAR-M therapies.
    Journal
    |
    CD5 (CD5 Molecule)
    5d
    Unusual Nasopharyngeal Localization of Chronic Lymphocytic Leukemia: A Case Report. (PubMed, Cureus)
    The patient was treated with six cycles of rituximab-bendamustine, resulting in complete regression of the nasopharyngeal mass and reduction in splenomegaly, with minimal residual lymphadenopathy and good clinical and biological tolerance. This case highlights the importance of considering CLL in the differential diagnosis of nasopharyngeal masses and emphasizes the role of combined imaging, histology, and immunophenotyping in establishing an accurate diagnosis and guiding appropriate management.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive
    |
    Rituxan (rituximab) • bendamustine
    8d
    Nano catalyzed green synthesis of chalcone derivatives and its anti-oxidant and anti-lung cancer potential validated through in vitro experimentals, in silico quantum chemical, molecular docking and simulation studies. (PubMed, In Silico Pharmacol)
    Drug likeness analysis results revealed that chalcone derivatives CD5, CD8, and CD9 and reference standard drugs lorlatinib and topotecan showed no violations against all five drug likeness rules. Current study overcomes these challenges by employing green nanocatalysts (Al(OH)₃ and Ti/Fe@Al(OH)₃) for eco-friendly, high-yield synthesis and computational screening to design potent, multi-target lung cancer therapeutic chalcone compounds. The online version contains supplementary material available at 10.1007/s40203-026-00599-3.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • CD5 (CD5 Molecule) • CD9 (CD9 Molecule)
    |
    Lorbrena (lorlatinib) • topotecan
    9d
    CD5-positive diffuse large B-Cell lymphoma presenting with protein-losing enteropathy. (PubMed, J Clin Exp Hematop)
    Chemotherapy with rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH-R) led to prompt improvement in serum albumin levels and resolution of the protein-losing enteropathy. Subsequent high-dose chemotherapy with autologous stem cell transplantation has maintained remission. Given the rarity of this presentation and its strong similarity to a previously reported case of CD5-positive DLBCL with protein-losing enteropathy, we propose that this might represent a distinct clinical entity.
    Journal
    |
    CD5 (CD5 Molecule)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine
    10d
    Analysis of ten cases of Acute lymphoblastic leukemia with non-KMT2A::AFF1 transcriptional variant 11q23 rearrangements (PubMed, Zhonghua Yi Xue Yi Chuan Xue Za Zhi)
    The 11q23 rearrangement ALL with non-KMT2A::AFF1 transcript is mainly KMT2A::MLLT1, T-ALL is more common, and the rate of chromosomal karyotype detection is relatively low. Persistent positive KMT2A-r is unfavorable for patient survival, and allo-HSCT during the CR1 period may improve patient survival.
    Retrospective data • Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • KMT2A (Lysine Methyltransferase 2A) • CD38 (CD38 Molecule) • WT1 (WT1 Transcription Factor) • CD22 (CD22 Molecule) • AFF1 (AF4/FMR2 Family Member 1) • CD34 (CD34 molecule) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • MLLT3 (MLLT3 Super Elongation Complex Subunit) • CD2 (CD2 Molecule) • AFDN (Afadin, Adherens Junction Formation Factor) • FUT4 (Fucosyltransferase 4) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    KMT2A rearrangement
    10d
    Primary Classical Hodgkin Lymphoma of the Urinary Bladder: Expanding the Spectrum of Bladder Lymphoid Neoplasms. (PubMed, Int J Surg Pathol)
    In the absence of systemic involvement, the patient was diagnosed with primary classical Hodgkin lymphoma of the bladder. This rare presentation highlights the importance of considering classical Hodgkin lymphoma in the differential diagnosis of bladder tumors with atypical morphology.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule) • CD79A (CD79a Molecule) • MME (Membrane Metalloendopeptidase)
    14d
    Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • celecoxib oral
    16d
    A Case of Angioimmunoblastic T-Cell Lymphoma Misdiagnosed as Eczema-Like Dermatitis in an Elderly Patient. (PubMed, Clin Cosmet Investig Dermatol)
    This case underscores the diagnostic complexity of AITL presenting with predominant allergic-like skin lesions and highlights the importance of considering underlying lymphoproliferative disorders in elderly patients with persistent, recurrent, or atypical dermatoses. Timely histopathological and immunophenotypic evaluation is essential for accurate diagnosis and appropriate management.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • MME (Membrane Metalloendopeptidase)
    17d
    A challenging case of facial oedemas revealing a systemic peripheral T-cell lymphoma, not otherwise specified. (PubMed, Eur J Dermatol)
    In our case, as extracutaneous disease was present from the beginning, the diagnosis would be better classified as systemic (non-primary cutaneous) PTCL-NOS. This report emphasizes the importance of repeated biopsies and expert reviews for diagnosing and managing PTCL, which can have a highly variable and poor prognosis.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD5 (CD5 Molecule) • GZMB (Granzyme B) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule) • PRF1 (Perforin 1)
    17d
    The Causal Role of Circulating Inflammatory Cytokines in Brain Tumors: Insights from Genetic Epidemiology. (PubMed, Immunol Invest)
    For astrocytoma, risk factors included Eotaxin, Macrophage colony-stimulating factor 1, and Interleukin-8; protective factors were T-cell surface glycoprotein CD5 and Tumor necrosis factor ligand superfamily member 12. This Mendelian randomization study identified specific inflammatory cytokines associated with these tumors, providing direction for future mechanistic research.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • TNFA (Tumor Necrosis Factor-Alpha) • CD5 (CD5 Molecule) • CSF1 (Colony stimulating factor 1) • CCL11 (C-C Motif Chemokine Ligand 11) • FGF21 (Fibroblast Growth Factor 21) • AXIN1 (Axin 1) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand)